222 related articles for article (PubMed ID: 37935113)
21. Safety, Efficacy, and Biomarker Analysis of Toripalimab in Patients with Previously Treated Advanced Urothelial Carcinoma: Results from a Multicenter Phase II Trial POLARIS-03.
Sheng X; Chen H; Hu B; Yao X; Liu Z; Yao X; Guo H; Hu Y; Ji Z; Luo H; Shi B; Liu J; Wu J; Zhou F; He Z; Fan J; Wang W; Feng H; Yao S; Keegan P; Huang Y; Guo J
Clin Cancer Res; 2022 Feb; 28(3):489-497. PubMed ID: 34740921
[TBL] [Abstract][Full Text] [Related]
22. A multicenter, real-world study on effectiveness and safety of first-line modified PD-1 inhibitors with chemotherapy in advanced non-small cell lung cancer (aNSCLC) with drive gene-negative.
Li T; Chen C; Liu L; Qin J; Qiu L; Wang A; Dong W; Zhang G; Li Y; Zhao L; Zhang F; Hu Y
Cancer Med; 2024 Feb; 13(3):e7024. PubMed ID: 38400661
[TBL] [Abstract][Full Text] [Related]
23. Rethinking prognostic factors in locally advanced or metastatic urothelial carcinoma in the immune checkpoint blockade era: a multicenter retrospective study.
Ruiz-Bañobre J; Molina-Díaz A; Fernández-Calvo O; Fernández-Núñez N; Medina-Colmenero A; Santomé L; Lázaro-Quintela M; Mateos-González M; García-Cid N; López-López R; Vázquez S; Anido-Herranz U
ESMO Open; 2021 Apr; 6(2):100090. PubMed ID: 33740735
[TBL] [Abstract][Full Text] [Related]
24. Expression of HER2 in high-grade urothelial carcinoma based on Chinese expert consensus and the clinical effects of disitamab vedotin-tislelizumab combination therapy in the treatment of advanced patients.
Zhu K; Chang Y; Zhao D; Guo A; Cao J; Wu C; Guan Y; Ding S
Front Pharmacol; 2024; 15():1355081. PubMed ID: 38455962
[No Abstract] [Full Text] [Related]
25. TAS0313 plus Pembrolizumab for Post-Chemotherapy Immune Checkpoint Inhibitor-Naïve Locally Advanced or Metastatic Urothelial Carcinoma.
Nishiyama H; Yonese J; Kawahara T; Matsumoto R; Miyake H; Matsubara N; Uemura H; Eto M; Azuma H; Obara W; Terai A; Fukasawa S; Suekane S
Mol Cancer Ther; 2024 Apr; 23(4):532-540. PubMed ID: 38060587
[TBL] [Abstract][Full Text] [Related]
26. Atezolizumab in Patients with Metastatic Urothelial Carcinoma Who Have Progressed After First-line Chemotherapy: Results of Real-life Experiences.
Tural D; Ölmez ÖF; Sümbül AT; Artaç M; Özhan N; Akar E; Çakar B; Köstek O; Ekenel M; Erman M; Coşkun HŞ; Selçukbiricik F; Keskin Ö; Türköz FP; Oruç K; Bayram S; Yılmaz U; Bilgetekin İ; Yıldız B; Şendur MAN; Paksoy N; Dirican A; Erdem D; Selam M; Tanrıverdi Ö; Paydaş S; Urakçı Z; Atağ E; Güncan S; Ürün Y; Alkan A; Kaya AO; Özyükseler DT; Taşkaynatan H; Yıldırım M; Sönmez M; Başoğlu T; Gündüz Ş; Kılıçkap S
Eur Urol Focus; 2021 Sep; 7(5):1061-1066. PubMed ID: 33008789
[TBL] [Abstract][Full Text] [Related]
27. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial.
Yu EY; Petrylak DP; O'Donnell PH; Lee JL; van der Heijden MS; Loriot Y; Stein MN; Necchi A; Kojima T; Harrison MR; Hoon Park S; Quinn DI; Heath EI; Rosenberg JE; Steinberg J; Liang SY; Trowbridge J; Campbell M; McGregor B; Balar AV
Lancet Oncol; 2021 Jun; 22(6):872-882. PubMed ID: 33991512
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and Safety of Disitamab Vedotin Combined with Programmed Death-1 Inhibitor for Advanced Urothelial Cancer: A Case-Series Study.
Zhao H; Xu Z; Li C; Xu T; Zhang J; Jiao J; Yang B; Qin R; Yang L; Qin W; Jing Y
Adv Ther; 2024 Feb; 41(2):857-866. PubMed ID: 38048019
[TBL] [Abstract][Full Text] [Related]
29. Epidemiology and treatment patterns for locally advanced or metastatic urothelial carcinoma: a systematic literature review and gap analysis.
Hepp Z; Shah SN; Smoyer K; Vadagam P
J Manag Care Spec Pharm; 2021 Feb; 27(2):240-255. PubMed ID: 33355035
[No Abstract] [Full Text] [Related]
30. Checkpoint Inhibitors in Combination With Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors: The CHEERS Phase 2 Randomized Clinical Trial.
Spaas M; Sundahl N; Kruse V; Rottey S; De Maeseneer D; Duprez F; Lievens Y; Surmont V; Brochez L; Reynders D; Danckaert W; Goetghebeur E; Van den Begin R; Van Gestel D; Renard V; Dirix P; Ost P
JAMA Oncol; 2023 Sep; 9(9):1205-1213. PubMed ID: 37410476
[TBL] [Abstract][Full Text] [Related]
31. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.
Powles T; Csőszi T; Özgüroğlu M; Matsubara N; Géczi L; Cheng SY; Fradet Y; Oudard S; Vulsteke C; Morales Barrera R; Fléchon A; Gunduz S; Loriot Y; Rodriguez-Vida A; Mamtani R; Yu EY; Nam K; Imai K; Homet Moreno B; Alva A;
Lancet Oncol; 2021 Jul; 22(7):931-945. PubMed ID: 34051178
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness and safety of immune checkpoint inhibitor monotherapy in advanced upper tract urothelial carcinoma: A multicenter, retrospective, real-world study.
Su R; Chen Z; Hong D; Jiang S; Yuan Y; Cai X; Hu H; Fu C; Huang Z; Wang Z; Zheng B; Huang J; Wang Z; Bao Y; Cai M; Guo J; Chen M; Wei Q; Huang J; Xue W
Cancer Med; 2023 May; 12(9):10587-10596. PubMed ID: 36952461
[TBL] [Abstract][Full Text] [Related]
33. A Phase II Study of Weekly Docetaxel as Second-Line Chemotherapy in Patients With Metastatic Urothelial Carcinoma.
Kim YS; Lee SI; Park SH; Park S; Hwang IG; Lee SC; Sun JM; Lee J; Lim HY
Clin Genitourin Cancer; 2016 Feb; 14(1):76-81. PubMed ID: 26454620
[TBL] [Abstract][Full Text] [Related]
34. Bempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma: Results from PIVOT-02.
Siefker-Radtke AO; Cho DC; Diab A; Sznol M; Bilen MA; Balar AV; Grignani G; Puente E; Tang L; Chien D; Hoch U; Choudhury A; Yu D; Currie SL; Tagliaferri MA; Zalevsky J; Hurwitz ME; Tannir NM
Eur Urol; 2022 Oct; 82(4):365-373. PubMed ID: 35643589
[TBL] [Abstract][Full Text] [Related]
35. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
[No Abstract] [Full Text] [Related]
36. Tislelizumab in combination with gemcitabine plus cisplatin chemotherapy as first-line adjuvant treatment for locally advanced or metastatic bladder cancer: a retrospective study.
Ren X; Tian Y; Wang Z; Wang J; Li X; Yin Y; Chen R; Zhan Y; Zeng X
BMC Urol; 2022 Aug; 22(1):128. PubMed ID: 35987640
[TBL] [Abstract][Full Text] [Related]
37. A phase Ib/II dose expansion study of subcutaneous sasanlimab in patients with locally advanced or metastatic non-small-cell lung cancer and urothelial carcinoma.
Cho BC; Penkov K; Bondarenko I; Kurochkin A; Pikiel J; Ahn HK; Korożan ME; Osipov M; Odintsova S; Braiteh F; Ribas A; Grilley-Olson JE; Lugowska I; Bonato V; Damore MA; Yang W; Jacobs IA; Bowers M; Li M; Johnson ML
ESMO Open; 2023 Aug; 8(4):101589. PubMed ID: 37385154
[TBL] [Abstract][Full Text] [Related]
38. Chemotherapy following immune checkpoint inhibitors in patients with locally advanced or metastatic urothelial carcinoma.
Meynard L; Dinart D; Delaunay B; Fléchon A; Saldana C; Lefort F; Gravis G; Thiery-Vuillemin A; Cancel M; Coquan E; Ladoire S; Maillet D; Rolland F; Boughalem E; Martin S; Laramas M; Crouzet L; Abbar B; Falkowski S; Pouessel D; Roubaud G
Eur J Cancer; 2022 Nov; 175():43-53. PubMed ID: 36088671
[TBL] [Abstract][Full Text] [Related]
39. TALASUR trial: a single arm phase II trial assessing efficacy and safety of TALazoparib and Avelumab as maintenance therapy in platinum-Sensitive metastatic or locally advanced URothelial carcinoma.
Coquan E; Clarisse B; Lequesne J; Brachet PE; Nevière Z; Meriaux E; Bonnet I; Castera M; Goardon N; Boutrois J; Travers R; Joly F; Grellard JM; Thiery-Vuillemin A
BMC Cancer; 2022 Nov; 22(1):1213. PubMed ID: 36434554
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS).
Grivas P; Loriot Y; Morales-Barrera R; Teo MY; Zakharia Y; Feyerabend S; Vogelzang NJ; Grande E; Adra N; Alva A; Necchi A; Rodriguez-Vida A; Gupta S; Josephs DH; Srinivas S; Wride K; Thomas D; Simmons A; Loehr A; Dusek RL; Nepert D; Chowdhury S
BMC Cancer; 2021 May; 21(1):593. PubMed ID: 34030643
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
